Published Studies Related to Miacalcin Nasal (Calcitonin Nasal)
Well-designed clinical trials related to Miacalcin Nasal (Calcitonin Nasal)
Efficacy and harms of nasal calcitonin in improving bone density in young patients with inflammatory bowel disease: a randomized, placebo-controlled, double-blind trial. [2011.08]
Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. [2008.09.09]
A randomized double-blind placebo-controlled trial to investigate the effects of nasal calcitonin on bone microarchitecture measured by high-resolution peripheral quantitative computerized tomography in postmenopausal women - Study protocol. [2008.04.13]
Comparison of calcitonin versus calcitonin + resistance exercise as prophylaxis for osteoporosis in heart transplant recipients. [2006.04.27]
The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. [2006.03]
Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study. [2005.06]
The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study. [2005.01]
Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. [2004.12]
Effectiveness of salmon calcitonin nasal spray in the treatment of lumbar canal stenosis: a double-blind, randomized, placebo-controlled, parallel group trial. [2004.11.01]
The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial. [2004.04]
Calcitonin therapy in osteoporosis. [2004]
Effects of nasal calcitonin on bone mineral density following parathyroidectomy in patients with primary hyperparathyroidism. [2003]
Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture. [2002.12]
The effect of calcitonin treatment on plasma nitric oxide levels in post-menopausal osteoporotic patients. [2002.06]
A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. [2002.03]
A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. [2000.09]
Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. [2000.08]
Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate. [2000.06]
Effect of calcitonin on bone and connective tissue metabolism in hemiplegic patients: a two-year prospective study. [1999.10]
Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. [1999.02]
Effect of nasal salmon calcitonin on post-traumatic osteopenia following ankle fracture. A randomized double-blind placebo-controlled study in 24 patients. [1998.08]
Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study. [1997.12.15]
Intrapulmonary drug delivery of salmon calcitonin. [1997.10]
Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. [1997.10]
A double blind study of intranasal calcitonin for established postmenopausal osteoporosis. [1997.10]
Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. [1997.07]
Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. [1997.02]
Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. [1997.02]
Morning or evening administration of nasal calcitonin? Effects on biochemical markers of bone turnover. [1997.01]
Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. [1997]
A new biochemical marker of bone resorption for follow-up on treatment with nasal salmon calcitonin. [1996.07]
Salmon calcitonin in the prevention of bone loss at perimenopause. [1996.06]
Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. [1996.02]
Ultrasound parameters in osteoporotic patients treated with salmon calcitonin: a longitudinal study. [1996]
Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study. [1995.07]
A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss. [1995.05]
Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. [1995.05]
Prevention of bone loss in early nonsurgical and nonosteoporotic high turnover patients with salmon calcitonin: the role of biochemical bone markers in monitoring high turnover patients under calcitonin treatment. [1995.01]
Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study. [1994.11]
A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium. [1994.08]
Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. [1994.07]
Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. [1994.01]
Intranasal calcitonin suppresses increased bone resorption during short-term immobilization: a double-blind study of the effects of intranasal calcitonin on biochemical parameters of bone turnover. [1993.12]
Acute effects of nasal salmon calcitonin on calcium and bone metabolism. [1993.10]
Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation. [1993.09]
Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women. [1993.09]
Substance P, calcitonin gene-related peptide, and vasoactive intestinal peptide increase in nasal secretions after allergen challenge in atopic patients. [1993.07]
Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. [1993.06.17]
Lack of effect of nasal salmon calcitonin on cell-mediated immunity. [1993.03]
Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women. [1992.12]
Intranasal calcitonin for the prevention of bone erosion and bone loss in rheumatoid arthritis. [1992.06]
An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss. [1992.04]
[Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis] [1992.04]
Calcitonin nasal spray reduces opioid withdrawal syndrome without modification of endogenous opioid secretion. [1992.01]
The use of nasal calcitonin in the treatment of post-traumatic algodystrophy. [1991.08]
Effect of different doses of nasal salmon calcitonin on bone mass. [1991.05]
Calcitonin nasal spray in patients with chronic asthma: a double-blind crossover study vs placebo. [1991.04]
Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study. [1991.01]
Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism. [1991]
Assessment of the biological activity of synthetic salmon calcitonin by intranasal administration in healthy volunteers. [1991]
[Intranasal salmon calcitonin for the prophylaxis of bone mineral loss in steroid-treated chronic obstructive lung diseases ] [1990.09]
Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. A one-year follow-up study. [1990.07]
A comparison of the acute effects of subcutaneous and intranasal calcitonin. [1990.02]
The effect of different doses of nasal salmon calcitonin on plasma cyclic AMP and serum ionized calcium. [1990.01]
Salmon calcitonin given by nasal spray or by injection does not increase beta-endorphin levels in normal men. [1990]
Acute effect of the intranasal administration of salmon calcitonin in osteoporotic women. [1989.11]
Nasal calcitonin for treatment of established osteoporosis. [1989.04]
Well-designed clinical trials possibly related to Miacalcin Nasal (Calcitonin Nasal)
Intranasal noninhaled carbon dioxide for the symptomatic treatment of seasonal allergic rhinitis. [2008.01]
Treatment of osteopenia and osteoporosis in renal transplant children and adolescents. [2004.08]
[Double-blind study on the efficacy of long-term intermittent nasal elcatonin in recent postmenopausal women] [2000.08]
Intranasal civamide for the acute treatment of migraine headache. [2000.07]
Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. [1997.06]
Functional effects of phosphoramidon and captopril on exogenous neuropeptides in human nasal mucosa. [1995]
Prevention of corticosteroid bone loss. [1993]
Other research related to Miacalcin Nasal (Calcitonin Nasal)
Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials. [2011.04]
Scientific considerations for generic synthetic salmon calcitonin nasal spray products. [2011.03]
Oral salmon calcitonin--pharmacology in osteoporosis. [2010.11]
Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery. [2010.04.19]
Enhancement of nasal and intestinal calcitonin delivery by the novel Pheroid fatty acid based delivery system, and by N-trimethyl chitosan chloride. [2010.01.29]
[Calcitonin and his role in regulation of calcium-phosphate metabolism] [2010]
Development of Calcitonin Salmon Nasal Spray: similarity of peptide formulated in chlorobutanol compared to benzalkonium chloride as preservative. [2009.10]
Improved absorption of salmon calcitonin by ultraflexible liposomes through intranasal delivery. [2009.07]
Central giant cell lesion of the jaw: nonsurgical treatment with calcitonin nasal spray. [2009.06]
Marked increase of procalcitonin after the administration of anti-thymocyte globulin in patients before hematopoietic stem cell transplantation does not indicate sepsis: a prospective study. [2009]
Moderate leukocyte infiltration in the lower turbinate mucosa after a two-week intranasal administration of mometasone furoate, azelastine or salmon calcitonin. [2009]
[Calcitonin] [2008.10]
Intranasal complications in women with osteoporosis under treatment with nasal calcitonin spray: case reports and review of the literature. [2008.09]
Calcitonin-derived peptide carriers: mechanisms and application. [2008.03.01]
Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. [2008]
Calcitonin nasal spray for treatment of central giant cell granuloma: clinical, radiological, and histological findings and immunohistochemical expression of calcitonin and glucocorticoid receptors. [2007.08]
[The hypocalcemia effect of salmon calcitonin ultra-flexible liposomes after intranasal administration in rats] [2007.06]
Randomised placebo-controlled trial on the effectiveness of nasal salmon calcitonin in the treatment of lumbar spinal stenosis. [2007.02]
Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-L-cysteine as a mucolytic agent. [2006.10.10]
Randomised placebo-controlled trial on the effectiveness of nasal salmon calcitonin in the treatment of lumbar spinal stenosis. [2006.07.25]
Early effect of nasal salmon calcitonin on the bone marker Crosslaps. [2006.02]
Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis. [2005.12]
The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. [2005.09.29]
Clinical outcome of salmon calcitonin nasal spray treatment in postmenopausal women after total hip arthroplasty. [2005.07]
Effect of chitosan on the intranasal absorption of salmon calcitonin in sheep. [2005.06]
Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. [2005.03]
Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty. [2005]
|
